Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis

E. Susan Amirian; Quinn T. Ostrom; Georgina N. Armstrong; Rose K. Lai; Xiangjun Gu; Daniel I. Jacobs; Ali Jalali; Elizabeth B. Claus; Jill S. Barnholtz-Sloan; Dora Il'Yasova; Joellen M. Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Robert B. Jenkins; Daniel H. Lachance; Sara H. Olson; Jonine L. Bernstein; Ryan T. Merrell; Margaret R. Wrensch; Christoffer Johansen; Richard S. Houlston; Michael E. Scheurer; Sanjay Shete; Christopher I. Amos; Beatrice Melin; Melissa L. Bondy

doi:10.1158/1055-9965.epi-18-0702

Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis

E. Susan Amirian^*, Quinn T. Ostrom, Georgina N. Armstrong, Rose K. Lai, Xiangjun Gu, Daniel I. Jacobs, Ali Jalali, Elizabeth B. Claus, Jill S. Barnholtz-Sloan, Dora Il'Yasova, Joellen M. Schildkraut, Francis Ali-Osman, Siegal Sadetzki, Robert B. Jenkins, Daniel H. Lachance, Sara H. Olson, Jonine L. Bernstein, Ryan T. Merrell, Margaret R. Wrensch, Christoffer JohansenRichard S. Houlston, Michael E. Scheurer, Sanjay Shete, Christopher I. Amos, Beatrice Melin, Melissa L. Bondy

^*Corresponding author for this work

Department of Clinical Medicine

7 Citations (Scopus)

Abstract

Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- ¹⁷ ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

Original language	English
Journal	Cancer Epidemiology Biomarkers and Prevention
Volume	28
Issue number	3
Pages (from-to)	555-562
Number of pages	8
ISSN	1055-9965
DOIs	https://doi.org/10.1158/1055-9965.epi-18-0702
Publication status	Published - 2019

Access to Document

10.1158/1055-9965.epi-18-0702

https://cebp.aacrjournals.org/content/cebp/28/3/555.full.pdf

Cite this

Susan Amirian, E., Ostrom, Q. T., Armstrong, G. N., Lai, R. K., Gu, X., Jacobs, D. I., Jalali, A., Claus, E. B., Barnholtz-Sloan, J. S., Il'Yasova, D., Schildkraut, J. M., Ali-Osman, F., Sadetzki, S., Jenkins, R. B., Lachance, D. H., Olson, S. H., Bernstein, J. L., Merrell, R. T., Wrensch, M. R., ... Bondy, M. L. (2019). Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 28(3), 555-562. https://doi.org/10.1158/1055-9965.epi-18-0702

Susan Amirian, E, Ostrom, QT, Armstrong, GN, Lai, RK, Gu, X, Jacobs, DI, Jalali, A, Claus, EB, Barnholtz-Sloan, JS, Il'Yasova, D, Schildkraut, JM, Ali-Osman, F, Sadetzki, S, Jenkins, RB, Lachance, DH, Olson, SH, Bernstein, JL, Merrell, RT, Wrensch, MR, Johansen, C, Houlston, RS, Scheurer, ME, Shete, S, Amos, CI, Melin, B & Bondy, ML 2019, 'Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis', Cancer Epidemiology Biomarkers and Prevention, vol. 28, no. 3, pp. 555-562. https://doi.org/10.1158/1055-9965.epi-18-0702

@article{ef044a4442674f4db6dfbd61d29251fc,

title = "Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis",

abstract = " Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted. ",

author = "{Susan Amirian}, E. and Ostrom, {Quinn T.} and Armstrong, {Georgina N.} and Lai, {Rose K.} and Xiangjun Gu and Jacobs, {Daniel I.} and Ali Jalali and Claus, {Elizabeth B.} and Barnholtz-Sloan, {Jill S.} and Dora Il'Yasova and Schildkraut, {Joellen M.} and Francis Ali-Osman and Siegal Sadetzki and Jenkins, {Robert B.} and Lachance, {Daniel H.} and Olson, {Sara H.} and Bernstein, {Jonine L.} and Merrell, {Ryan T.} and Wrensch, {Margaret R.} and Christoffer Johansen and Houlston, {Richard S.} and Scheurer, {Michael E.} and Sanjay Shete and Amos, {Christopher I.} and Beatrice Melin and Bondy, {Melissa L.}",

year = "2019",

doi = "10.1158/1055-9965.epi-18-0702",

language = "English",

volume = "28",

pages = "555--562",

journal = "Cancer Epidemiology, Biomarkers & Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research (A A C R)",

number = "3",

}

TY - JOUR

T1 - Aspirin, NSAIDs, and glioma risk

T2 - Original data from the glioma international case-control study and a meta-analysis

AU - Susan Amirian, E.

AU - Ostrom, Quinn T.

AU - Armstrong, Georgina N.

AU - Lai, Rose K.

AU - Gu, Xiangjun

AU - Jacobs, Daniel I.

AU - Jalali, Ali

AU - Claus, Elizabeth B.

AU - Barnholtz-Sloan, Jill S.

AU - Il'Yasova, Dora

AU - Schildkraut, Joellen M.

AU - Ali-Osman, Francis

AU - Sadetzki, Siegal

AU - Jenkins, Robert B.

AU - Lachance, Daniel H.

AU - Olson, Sara H.

AU - Bernstein, Jonine L.

AU - Merrell, Ryan T.

AU - Wrensch, Margaret R.

AU - Johansen, Christoffer

AU - Houlston, Richard S.

AU - Scheurer, Michael E.

AU - Shete, Sanjay

AU - Amos, Christopher I.

AU - Melin, Beatrice

AU - Bondy, Melissa L.

PY - 2019

Y1 - 2019

N2 - Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

AB - Background: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the associations between glioma and aspirin/NSAID use, and to aggregate these findings with prior published studies using meta-analysis. Methods: The Glioma International Case-Control Study (GICC) consists of 4,533 glioma cases and 4,171 controls recruited from 2010 to 2013. Interviews were conducted using a standardized questionnaire to obtain information on aspirin/NSAID use. We examined history of regular use for ≥6 months and duration-response. Restricted maximum likelihood meta-regression models were used to aggregate site-specific estimates, and to combine GICC estimates with previously published studies. Results: A history of daily aspirin use for ≥6 months was associated with a 38% lower glioma risk, compared with not having a history of daily use [adjusted meta-OR ¼ 0.62; 95% confidence interval (CI), 0.54-0.70]. There was a significant duration-response trend (P ¼ 1.67 × 10- 17 ), with lower ORs for increasing duration of aspirin use. Duration-response trends were not observed for NSAID use. In the meta-analysis aggregating GICC data with five previous studies, there was a marginally significant association between use of aspirin and glioma (mOR = 0.84; 95% CI, 0.70-1.02), but no association for NSAID use. Conclusions: Our study suggests that aspirin may be associated with a reduced risk of glioma. Impact: These results imply that aspirin use may be associated with decreased glioma risk. Further research examining the association between aspirin use and glioma risk is warranted.

U2 - 10.1158/1055-9965.epi-18-0702

DO - 10.1158/1055-9965.epi-18-0702

M3 - Journal article

C2 - 30482874

AN - SCOPUS:85062407156

SN - 1055-9965

VL - 28

SP - 555

EP - 562

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

IS - 3

ER -

Aspirin, NSAIDs, and glioma risk: Original data from the glioma international case-control study and a meta-analysis

Abstract

Access to Document

Fingerprint

Cite this